UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)												
1. Name and Address of Reporting F Lin Patrick	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(First) C/O PROCESSA PHARMAC INC., 7380 COCA COLA DE	06/21/2021					X Office	X_Officer (give title below) Other (specify below) Chief Business - Strategy Off					
(Street) HANOVER, MD 21076	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.00 %	2 T (1									7.31.4
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code (Instr. 8)	(4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D)	Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Following	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		(Month/Day/Year)	Code	V	V Amount (D) Pr		Price					
Common Stock	06/21/2021		P		2,000	A \$:	401,737			D	
Reminder: Report on a separate line	Table II - I	ities beneficially over the security of the se	es Acquire	Perso contai the fo	ons who ined in orm dis	o respon this forr plays a c f, or Bene	n are currer	not requantly valid		formation spond unlestrol number	s	474 (9-02)
1. Title of Derivative Security (Instr. 3) 2. Conversion Opate (Month/Day Opation Security Security Security	Execution Dat y/Year) any	te, if Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	and Ex	` , , , , , , , , , , , , , , , , , , ,		Amo Unde Secu (Inst: 4)	Amount or	Derivative	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownersh Form of Derivativ Security: Direct (I or Indire	/
		Code V	(A) (D)	Exerci		Date	Title	Number of Shares				
Reporting Owners				Relatio	onships				7			

		Relationships					
Reporting Owner Name / Address		Director	10% Owner	Officer	Other		
	Lin Patrick C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Business - Strategy Off			

Signatures

/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact	06/22/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.